He was instrumental in critically appraising clinical data from a translational standpoint, specifically evaluating the cardiorenal implications of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus. Here, GLP1R is linked to type 2 diabetes mellitus.